IDOASIS 2002 SL

Their core work

IDOASIS 2002 SL is a Madrid-based biotech and agri-innovation SME that operates at the intersection of advanced plant science and applied bioeconomy. In plant biotechnology, they work with CRISPR/Cas9 genome editing, agroinfiltration, cisgenesis, and other new plant breeding techniques applied to Nicotiana species for molecular farming — essentially engineering tobacco plants to produce valuable compounds. In parallel, they work on valorizing biomass from tree and shrub species grown on marginal lands, extracting or converting this material into bioplastics, essential oils, activated carbon, biochar, and wood-based products. They bring specialist scientific and technical expertise to large European research consortia rather than leading projects themselves.

What they specialise in

How they've shifted over time

IDOASIS's first H2020 project (Newcotiana, 2018) was firmly rooted in precision plant biotechnology — genome editing tools, agroinfiltration protocols, and engineered Nicotiana platforms for molecular farming. By 2020, their second project (BeonNAT) had shifted the application domain entirely toward sustainable land use and circular materials, with keywords such as shrub, marginal lands, biochar, bioplastic, and activated carbon replacing the earlier molecular biology vocabulary. This is either a deliberate pivot toward applied circular bioeconomy work or evidence that IDOASIS is a versatile SME with multiple technical service areas that it deploys across different consortium calls.

IDOASIS appears to be moving from laboratory-focused plant biotechnology toward applied circular bioeconomy, suggesting future project interests will likely span sustainable land use, bio-based materials, and the commercialization of plant-derived specialty chemicals.

How they like to work

IDOASIS has participated in 2 projects and coordinated none, positioning them consistently as a specialist contributor that joins consortia led by others. Across just 2 projects they engaged 35 unique partners in 10 countries, which indicates they work within large, multinational Research and Innovation Action consortia rather than tight bilateral arrangements. This profile — niche expertise, no coordination appetite, broad partner exposure — suggests they are straightforward to bring into a consortium but unlikely to take on administrative or managerial responsibility.

35 unique consortium partners across 10 countries from only 2 projects is a notably broad network for an SME of this size, reflecting the large consortium structures typical of RIA projects in agri-biotech. Their collaboration footprint is European in scope, consistent with the Horizon 2020 programmes they joined.

What sets them apart

IDOASIS occupies an unusual dual position for a small Spanish SME: they hold credible expertise in both precision plant science (CRISPR, molecular farming) and downstream applied bioeconomy (bioplastics, biochar, essential oils from marginal biomass), domains that rarely sit in the same organization. This breadth makes them a useful wildcard partner for consortia that need to bridge upstream biotechnology and downstream market application in a single SME slot. Their Madrid base and demonstrated RIA experience also make them eligible and accustomed to the workload and reporting demands of large EU collaborative projects.

Highlights from their portfolio

• Newcotiana
  One of only a handful of H2020 projects using CRISPR and agroinfiltration on tobacco species as a molecular farming platform — a high-profile application of new plant breeding techniques with potential pharmaceutical and industrial relevance.
• BeonNAT
  Largest project by EC contribution (€360,222) and the longest in duration (2020-2025), targeting the full value chain from marginal-land shrubs to commercial bioproducts including bioplastics, biochar, and essential oils.